[
  {
    "ts": null,
    "headline": "Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties",
    "summary": "Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (\"Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Phil",
    "url": "https://finnhub.io/api/news?id=eb4b0ff7212aeedd380f62af91bb7b2918b274671c394e13fec795ed99b6c85e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749592500,
      "headline": "Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties",
      "id": 135171248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (\"Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Phil",
      "url": "https://finnhub.io/api/news?id=eb4b0ff7212aeedd380f62af91bb7b2918b274671c394e13fec795ed99b6c85e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=bd3439ccb21672eeb8b728fc378c2a71dc625eca119eb5475fcf0cea5e6ccf82",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749573480,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 135185598,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=bd3439ccb21672eeb8b728fc378c2a71dc625eca119eb5475fcf0cea5e6ccf82"
    }
  },
  {
    "ts": null,
    "headline": "Nuvation Bio: Judgement Day Grows Closer",
    "summary": "Nuvation Bio: Judgement Day Grows Closer",
    "url": "https://finnhub.io/api/news?id=d3314bdd8ef62a65bf2cde13f476284544ec89b0cc499a2474a766e10012db32",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749568773,
      "headline": "Nuvation Bio: Judgement Day Grows Closer",
      "id": 135169528,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d3314bdd8ef62a65bf2cde13f476284544ec89b0cc499a2474a766e10012db32"
    }
  },
  {
    "ts": null,
    "headline": "5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen",
    "summary": "Fortune has partnered with Indiggo to measure Return On Leadership, called the ROL100. Read which dividend stocks we recommend from the list.",
    "url": "https://finnhub.io/api/news?id=ab3738e113bcda4ee72d65cbb95f1689283e6dabb69ca10d1bd4dbb1aad2f56e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749559623,
      "headline": "5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen",
      "id": 135161067,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1410966689/image_1410966689.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Fortune has partnered with Indiggo to measure Return On Leadership, called the ROL100. Read which dividend stocks we recommend from the list.",
      "url": "https://finnhub.io/api/news?id=ab3738e113bcda4ee72d65cbb95f1689283e6dabb69ca10d1bd4dbb1aad2f56e"
    }
  }
]